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Abstract
Guidelines and experts note that patients with atrial fibrillation require regular renal function monitoring to ensure safe use
of direct oral anticoagulants (DOACs). Insufficient monitoring could lead to inappropriate dosing and adverse events. Our
objective was to describe the frequency of insufficient creatinine monitoring among patients on DOACs, and to describe
clinical factors associated with insufficient monitoring. We hypothesized that renal impairment would be associated with
insufficient monitoring. A retrospective cohort study was performed with data from the Michigan Anticoagulant Quality
Improvement Initiative. Patients were included if they initiated DOAC therapy for stroke prevention related to atrial fibrillation, remained on therapy for ≥ 1 year, and had baseline creatinine and weight measurements. Creatinine clearance (CrCl)
was calculated via Cockcroft-Gault equation. Our outcome was the presence of insufficient creatinine monitoring, defined
as: < 1 creatinine level/year for patients with CrCl > 50, or < 2 creatinine levels/year for patients with CrCl ≤ 50. Multivariable analysis was done via logistic regression. Study population included 511 patients. In overall, 14.0% of patients received
insufficient monitoring. Among patients with CrCl > 50, 11.5% had < 1 creatinine level/year. Among patients with CrCl ≤ 50,
27.1% received < 2 creatinine levels/year. Baseline renal dysfunction was associated with a higher likelihood of insufficient
creatinine monitoring (adjusted odds ratio 3.64, 95% confidence interval 1.81–7.29). This shows a significant gap in the
monitoring of patients on DOACs—patients with renal impairment are already at higher risk for adverse events. Future studies are needed to describe the barriers in monitoring these patients and to identify how to optimally address them.
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• Atrial fibrillation patients on direct anticoagulants

(DOACs) require renal function monitoring.

• It is unknown how many of these patients have creatinine

monitoring according to guidelines.

• One in seven patients on DOACs for atrial fibrillation

have insufficient creatinine monitoring.

• Baseline renal impairment was associated with higher

risk of insufficient creatinine monitoring.

• Studies are needed to describe why this care gap exists

and what steps would best address it.
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Introduction
Direct oral anticoagulants (DOACs) have become the
standard of care for stroke prevention related to non-valvular atrial fibrillation (AF), given their efficacy, safety,
and convenience as compared to warfarin [1, 2]. While
DOACs do not require routine anticoagulation monitoring, they do require special attention to renal function [3].
A significant proportion of patients with AF have coexistent renal impairment or experience fluctuations in renal
function while on treatment [1, 4]. At baseline, patients
with comorbid AF and renal dysfunction are at higher
risk for both thrombotic and bleeding events [5]. DOAC
pharmacokinetics are influenced by kidney function; inappropriate dosing is also associated with a higher incidence
of adverse events [3, 6]. For this reason, recommendations state that patients with AF should have a creatinine
drawn before starting treatment, that patients with normal
renal function have creatinine levels drawn annually, and
that patients with renal impairment obtain more frequent
monitoring [1, 2, 7–9].
A significant proportion of patients are started on
DOAC therapy without a baseline creatinine or are dosed
inappropriately due to fluctuations in renal function [4,
10]. Unfortunately, data on how clinicians longitudinally
monitor patients’ renal function while on DOACs is limited. Our study aimed to describe clinicians’ creatinine
monitoring patterns in the context of DOAC therapy, in
addition to describing the relationship between various
clinical factors and the possibility of receiving insufficient
monitoring. Chief among these factors was the presence
of pre-existing renal impairment. We hypothesized that
patients with renal impairment would be more likely to
receive insufficient monitoring.

Methods
This retrospective cohort study was conducted using
previously collected data from the Michigan Anticoagulant Quality Improvement Initiative (MAQI2), sponsored
by Blue Cross Blue Shield of Michigan. Among the six
M AQI 2 sites, four collect data on randomly selected
patients initiating DOAC therapy. More details on M
 AQI2
have been published previously [11, 12].
Our study size was determined by the maximum number of patients who met our inclusion criteria within the
MAQI2 database. For this analysis, we included patients
(> 18 years old) who initiated DOAC therapy for stroke
prevention in non-valvular AF. Patient enrollment spanned
from November 2015–February 2017. Included patients
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needed to have a baseline weight, baseline creatinine,
and ≥ 1 year of follow-up. Patients with creatinine clearance (CrCl) < 15 mL/min/1.73 m 2 were excluded since
these patients are not eligible for DOAC therapy [1]. This
cohort included patients on apixaban, rivaroxaban, and
dabigatran; no patients were on edoxaban.
Demographic and clinical variables are abstracted from
the medical record at the time of DOAC initiation and every
6 months thereafter. The follow-up period for each patient
spanned from enrollment until data acquisition from the
database in June 2018. Data was collected from the medical
record by trained abstractors according to variable definitions defined previously by the MAQI2 collaborative [11].
The MAQI2 collaborative performs random audits to ensure
accurate data abstraction. To describe our population, thromboembolic risk was quantified via CHA2DS2-VASC score;
bleeding risk was quantified via HAS-BLED score [1, 13].
CrCl was calculated using the Cockcroft-Gault equation
using actual body weight, as this method stratified patients
by renal function in the DOAC clinical trials [14–17].
Our primary endpoint was the presence of insufficient
creatinine monitoring. All guidelines recommend at least
once yearly creatinine levels in patients without kidney
dysfunction [2, 7–9]. It is generally recommended to obtain
more frequent creatinine monitoring amongst patients with
renal impairment; recommended intervals generally vary
between every 3-6 months (Supplementary Table 1) [2, 7–9].
Given the retrospective nature of this study and our aim to
describe natural clinical monitoring patterns, the physicians
within these health systems were not given specific instructions on how to monitor renal function prior to collection
of this data.
Our criteria defined insufficient monitoring as < 1 creatinine level/year for patients with CrCl > 50, or < 2 creatinine
levels/year for patients with CrCl ≤ 50. Our analysis aimed
to describe the prevalence of insufficient creatinine monitoring in our entire study population, and between patients with
normal versus impaired renal function. We defined renal
impairment as CrCl ≤ 50 since this is the threshold where
DOAC dosing changes [3]. We performed two sensitivity
analyses. In one analysis, the outcome was obtaining fewer
than 1 creatinine level/year—to see if patients with renal
impairment receive the same monitoring as other patients.
In our other sensitivity analysis, we imposed stricter criteria for creatinine monitoring, approximating those given
by the European Heart Rhythm Association (EHRA) [2].
In this analysis insufficient monitoring was considered: < 1
creatinine level/year for patients with CrCl > 60, < 2 creatinine levels/year for those with CrCl > 30–60, or < 3 creatinine levels/year for those with CrCl 15–30 [2]. Since EHRA
guidelines recommend more frequent creatinine monitoring
at CrCl of 60, renal impairment in this sensitivity analysis
was defined as CrCl ≤ 60 [2].
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Univariate comparisons were done via t test, Mood’s
median test, Fisher’s exact test, and Chi square. To determine the relationship between clinical factors and creatinine
monitoring, a multivariable logistical regression model was
developed. Variables included baseline renal impairment,
age, insurance status, DOAC used, comorbid heart failure,
and comorbid hypertension. No effect modifier or interaction
terms were included in our model. A two-sided p < 0.05 was
considered statistically significant. All analyses were done
in SAS 9.4 (SAS Institute, Inc., Cary, NC).

Results
We identified 1052 patients from the MAQI2 registry on
DOAC therapy for AF during the study period. Of those, 535
patients were excluded for having < 1 year of follow-up and
6 were excluded for missing data on enrollment or followup. Our final cohort was 249/511 (48.7%) male; mean age
was 72.8 ± 11.0 years, 378/511 (74.0%) were on apixaban,
and 85/511 (16.6%) had a baseline CrCl ≤ 50 (Table 1). Our
study population is comparable to larger epidemiological
cohorts in terms of age and racial makeup; our cohort has a
higher female proportion and a lower proportion with renal
impairment [18–20]. Patients were treated for a mean of
521.6 ± 149.4 days (Table 1).
Overall, 72/511 (14.1%) patients had insufficient creatinine monitoring. Patients with insufficient monitoring were
on DOAC therapy longer than the patients with sufficient
monitoring (Table 1). There were no significant differences
in the choice of DOAC between classes of CrCl (Table 2).
The median number of clinical encounters also did not differ
between classes of CrCl (Table 2).
As shown in Table 2, 23/89 (27.1%) patients with
CrCl ≤ 50 had insufficient renal monitoring, as compared
to 49/246 (11.5%) of patients with CrCl > 50. In our multivariable analysis, baseline renal impairment was associated with higher odds of insufficient monitoring (adjusted
odds ratio [aOR] 3.64, 95% confidence interval [CI] 1.817.29, Supplementary Table 2). Patients with heart failure
were less likely to have insufficient monitoring (aOR 0.39,
95% CI 0.17–0.91, Supplementary Table 2). When using
stricter monitoring criteria in our sensitivity analysis, 47/376
(12.5%) of patients with CrCl > 60 and 52/135 (38.5%) of
patients with CrCl ≤ 60 received insufficient monitoring
(data not shown). Having a CrCl ≤ 60 was associated with
insufficient monitoring (aOR 5.05, 95% CI 2.84–8.96, Supplementary Table 3). Heart failure was associated with a
lower likelihood of insufficient monitoring (aOR 0.49,
95% CI 0.24–0.98, Supplementary Table 3). Sensitivity
analysis also demonstrated that patients with CrCl ≤ 50 and
CrCl > 50 were similarly likely to have at least once yearly
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creatinine levels (aOR 0.61, 95% CI 0.22–1.75, Supplementary Table 4).

Discussion
In our cohort, one in seven patients had insufficient monitoring of their renal function while on DOAC therapy.
Among patients with renal dysfunction, more than one in
four patients did not receive twice-yearly creatinine testing,
despite international guidelines recommending this in most
chronic kidney disease (CKD) patients [9].
Our results demonstrate that many CKD patients who are
treated with DOACs are not receiving frequent enough renal
testing. Evidence on this topic has been scarce. A recent
Spanish study observed that 39% of their patients received
inadequate monitoring, and found decreasing CrCl to be
associated with inadequate monitoring [21]. While similar
results were found, national differences in the health care
systems and guidelines limit the generalizability of this
study to the United States [22]. To our knowledge, this is the
first study to characterize these creatinine monitoring patterns in an American cohort. Our study provides data over
a longer follow-up period and demonstrates a gap in care
even when using lenient monitoring criteria. This is important—within a 2-year follow-up period, 12% of patients on
DOACs had a change in renal function, a quarter of which
was significant enough to require a dosage change [4]. Misdosing of DOACs has been associated with an increased risk
of major bleeding, hospitalization, and death [6].
Strengths of this study include the use of chart abstracted
and randomly audited data that reflects practice-based, unselected clinical patterns. Another strength is that our database
includes data from four clinical sites, including academic
and community-based centers. Our study does have limitations that warrant consideration. There is variation in recommendations for appropriate renal monitoring in DOAC
patients, although we found that a considerable proportion of patients had insufficient monitoring by both strict
and conservative definitions. Our sample size may limit
the statistical power to detect weaker influences on creatinine monitoring. It is possible that these patients received
creatinine testing outside of our database, although this is
unlikely since all patients in MAQI2-DOAC have primary
care office records within our participating health care systems. Our study has limited generalizability among certain
DOACs, including dabigatran and edoxaban, due to having
few patients in the analysis. Finally, as with all observational
studies, we cannot adjust for unmeasured confounders.
In summary, our results demonstrate an association
between renal impairment and increased odds of insufficient
creatinine monitoring. Future studies with larger populations
should explore why this association occurs, what impact it

503

Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for…
Table 1  Patient demographics
and clinical characteristics, by
level of creatinine monitoring

Overall

Frequency of creatinine
monitoringa
Sufficient

No. (%)
Age, mean (SD), years
Male, no. (%)
Race, no. (%)b
Caucasian
Black
Other
Weight, mean (SD), kg
Insurance status, no. (%)
Private
Medicaid
Unknown
CHA2DS2-VASc, mean (SD)
HAS-BLED, mean (SD)
Comorbidities, no. (%)
Hypertension
Congestive heart failure
History of stroke
History of bleeds prior to DOAC*
Drug or alcohol use
DOAC used, no. (%)
Apixaban
Rivaroxaban
Dabigatran
Duration of therapy at follow-up, mean (SD), days
Number of clinical encounters/year, median(IQR)
Initiated as inpatient, no. (%)
Prescriber specialty
Cardiology
Primary care provider*
Other
Baseline CrCl, no. (%), mL/min/1.73 m2
> 50*
> 30–50*
15–30
Creatinine levels/year, median (IQR)*
NSAID, aspirin, antiplatelet use, no. (%)*
Loop diuretic use, no. (%)

Insufficient

511
72.8 (11.0)
249 (48.7)

439 (85.9)
72.6 (10.9)
217 (49.4)

72 (14.1)
74.2 (11.4)
32 (44.4)

430 (84.1)
42 (8.2)
22 (4.3)
90.5 (25.6)

374 (85.2)
36 (8.2)
17 (3.9)
91.4 (26.2)

56 (77.8)
6 (8.3)
5 (6.9)
85.2 (20.3)

136 (26.6)
358 (70.1)
17 (3.3)
3.6 (1.6)
2.7 (1.2)

117 (26.7)
310 (70.6)
2 (2.7)
3.6 (1.5)
2.7 (1.2)

19 (26.4)
48 (66.7)
5 (6.9)
3.5 (1.7)
2.5 (1.1)

435 (85.1)
83 (16.2)
61 (11.9)
160 (31.3)
22 (4.3)

370 (84.3)
76 (17.3)
51 (11.6)
145 (33.0)
21 (4.8)

65 (90.3)
7 (9.7)
10 (13.9)
15 (20.8)
1 (1.4)

327 (74.5)
104 (23.7)
8 (1.8)
513.5 (148.6)
2.0 (2.0–2.0)
186 (42.4)

51 (70.8)
20 (27.8)
1 (1.4)
571.2 (145.4)
2.0 (2.0–2.0)
32 (44.4)

270 (52.8)
160 (31.3)
81 (15.9)

227 (51.7)
145 (33.0)
67 (15.3)

43 (59.7)
15 (20.8)
14 (19.4)

426 (83.4)
76 (14.9)
9 (1.8)
2.0 (1.3–2.0)
209 (40.9)
9 (1.8)

377 (85.9)
54 (12.3)
8 (1.8)
2.0 (1.5–2.0)
187 (42.6)
8 (1.8)

378 (74.0)
124 (24.3)
9 (1.8)
521.6 (149.4)
2.0 (2.0–2.0)
218 (42.7)

49 (68.1)
22 (30.6)
1 (1.4)
0.67 (0.5–0.97)
22 (30.6)
1 (1.4)

*Statistically significant at alpha of 0.05
a

Insufficient monitoring defined as < 1 creatinine level/year for patients with creatinine clearance
(CrCl) > 50 mL/min, or < 2 creatinine levels/year for patients with CrCl ≤ 50 mL/min. CrCl estimated by
Cockcroft-Gault
b

The number of patients within racial categories does not add to the full population size since 17 patients
had missing racial data

may have on clinical outcomes, and what steps would best
mitigate this care gap.

Author contributions Concept and design: MMG, YL, EKR, MAA,
SK, MD, JBF, GDB. Acquisition, analysis, or interpretation of data:
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the manuscript for important intellectual content: MMG, YL, XK,
DD, EKR, MAA, SK, MD, JBF, GDB. Statistical analysis: YL, XK.
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Table 2  Creatinine monitoring characteristics, by baseline renal function

waiver of informed consent from our respective Institutional Review
Board.

Baseline CrCl (mL/
min/1.73 m2)
> 50
No. (%)
Creatinine values/year, median
(IQR)
Creatinine ≥ 1 time/year, no. (%)
Creatinine ≥ 2 times/year, no. (%)*
Number of clinical encounters/year,
median (IQR)
DOAC used, no. (%)
Apixaban
Rivaroxaban
Dabigatran

> 30–50 15–30

426 (83.4) 76 (14.9) 9 (1.8)
2 (1–2) 2 (1.5–2) 2 (2–2)
377 (88.5) 71 (93.4) 9 (100)
253 (59.4) 54 (71.1) 8 (88.9)
2 (2–2) 2 (2–2) 2 (2–2)

310 (72.8) 60 (78.9) 8 (88.9)
107 (25.1) 16 (21.1) 1 (11.1)
9 (2.1) 0
0

Creatinine clearance (CrCl) calculated by Cockcroft–Gault equation
*Statistically significant at alpha of 0.05
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